These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8408454)

  • 1. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.
    Reasner CA; Stone MD; Hosking DJ; Ballah A; Mundy GR
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1067-71. PubMed ID: 8408454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical effects of a calcium supplement in postmenopausal women with primary hyperparathyroidism.
    Horowitz M; Wishart JM; Need AG; Morris HA; Nordin BE
    Horm Metab Res; 1994 Jan; 26(1):39-42. PubMed ID: 8150422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
    Singer FR; Clemens TL; Eusebio RA; Bekker PJ
    J Clin Endocrinol Metab; 1998 Jun; 83(6):1906-10. PubMed ID: 9626117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of diphosphonate in primary hyperparathyroidism.
    Kaplan RA; Geho WB; Poindexter C; Haussler M; Dietz GW; Pak CY
    J Clin Pharmacol; 1977 Jul; 17(7):410-9. PubMed ID: 195983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
    Siris ES; Chines AA; Altman RD; Brown JP; Johnston CC; Lang R; McClung MR; Mallette LE; Miller PD; Ryan WG; Singer FR; Tucci JR; Eusebio RA; Bekker PJ
    J Bone Miner Res; 1998 Jun; 13(6):1032-8. PubMed ID: 9626635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normocalcemic primary hyperparathyroidism: resistance to PTH effect on tubular reabsorption of calcium.
    Gardin JP; Paillard M
    Miner Electrolyte Metab; 1984; 10(5):301-8. PubMed ID: 6493158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of adenosine 3',5'-monophosphate excretion and an oral calcium tolerance test in the diagnosis of mild primary hyperparathyroidism.
    Madvig P; Young G; Marcus R
    J Clin Endocrinol Metab; 1984 Mar; 58(3):480-7. PubMed ID: 6319454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
    Brown JP; Hosking DJ; Ste-Marie L; Johnston CC; Reginster J; Ryan WG; Johnson TD; Bekker PJ
    Calcif Tissue Int; 1999 Feb; 64(2):93-9. PubMed ID: 9914313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clodronate in the medical management of hyperparathyroidism.
    Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
    Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone.
    Maruani G; Hertig A; Paillard M; Houillier P
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4641-8. PubMed ID: 14557434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment.
    Adami S; Mian M; Bertoldo F; Rossini M; Jayawerra P; O'Riordan JL; Lo Cascio V
    Clin Endocrinol (Oxf); 1990 Sep; 33(3):391-7. PubMed ID: 2147599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
    Schwarz A; Merkel S; Leitolf H; Haller H
    Transplantation; 2011 Mar; 91(5):560-5. PubMed ID: 21192318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
    Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion.
    Yarrington JT; Capen CC; Black HE; Re R; Potts JT; Geho WB
    Am J Pathol; 1976 Jun; 83(3):569-88. PubMed ID: 180813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bisphosphonate therapy and parathyroidectomy on the urinary excretion of galactosylhydroxylysine in primary hyperparathyroidism.
    LoCascio V; Braga V; Bertoldo F; Bettica P; Pasini AF; Stefani L; Moro L
    Clin Endocrinol (Oxf); 1994 Jul; 41(1):47-51. PubMed ID: 8050131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating parathyroid hormone activity: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism.
    Marx SJ; Spiegel AM; Brown EM; Windeck R; Gardner DG; Downs RW; Attie M; Aurbach GD
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1190-7. PubMed ID: 233692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) on the ultrastructure of parathyroid glands and plasma immunoreactive parathyroid hormone in pregnant cows fed a low calcium diet.
    Yarrington JT; Capen CC; Black HE; Re R; Potts JT; Geho WB
    Lab Invest; 1977 Apr; 36(4):402-12. PubMed ID: 191694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.